Results 221 to 230 of about 94,246 (299)

A new investigation of nonalcoholic fatty liver disease: Effects of hypoxia on mitochondrial function and lipid droplet autophagy. [PDF]

PLoS One
Tian M, Zhang Y, Liu Z, Zhao N, Huang D, Hou J, Sun L, Jiang Y, Zhang G, Ma Y.   +9 more
europepmc   +1 more source

Fat‐Corrected Non‐Gaussian Diffusion MRI for Liver Fibrosis Assessment in Metabolic Dysfunction‐Associated Steatotic Liver Disease

Journal of Magnetic Resonance Imaging, Volume 63, Issue 2, Page 497-507, February 2026.
ABSTRACT Background In patients with metabolic dysfunction‐associated steatotic liver disease (MASLD), non‐Gaussian diffusion—weighted imaging (DWI) has been proposed for the diagnosis of liver fibrosis, but its measurement is partially confounded by steatosis.
Omaïma Saïd, Sabrina Doblas, Valérie Paradis, Pierre Bedossa, Dominique Valla, Cédric Laouénan, Laurent Castera, Bernard E. Van Beers, Philippe Garteiser   +8 more
wiley   +1 more source

Nonlinear Association Between BMI and Depression Among Nonalcoholic Fatty Liver Disease: NHANES (2017-2018). [PDF]

Behav Neurol
Peng H, Zhou D, Dai Y, Chen W.
europepmc   +1 more source

Inflammation and Cancer: Molecular Mechanisms and Therapeutic Targets

MedComm, Volume 7, Issue 2, February 2026.
Chronic inflammation fuels tumorigenesis via “internal drivers” and “external attractions.” Targeting these core mechanisms with combined therapies/novel deliveries enables precise, potent anti‐inflammatory–antitumor treatment. ABSTRACT Inflammation is a core pathological factor regulating tumor initiation, progression, and therapeutic resistance, and ...
Xiaodie Liu, Ziyuan Wang, Huirong Zhu, Yicun Han, Qing Ji   +4 more
wiley   +1 more source

<i>Lygodium japonicum</i> Herb Ameliorates Nonalcoholic Fatty Liver Disease by Inhibiting Hepatic Lipid Accumulation and Inflammatory Response in ob/ob Mice. [PDF]

ACS Omega
Li S, Chen Y, Fan P, Feng C, Liao Z, Zeng X.   +5 more
europepmc   +1 more source

Progress in RNA‐Targeted Therapeutics for Human Diseases

MedComm, Volume 7, Issue 2, February 2026.
RNA‐targeted therapies are revolutionizing molecular medicine by transitioning from a “protein‐centric” focus to an “RNA‐regulatory network” approach. Leveraging RNA's diverse roles in gene regulation, signaling, and epigenetic modifications, advanced platforms such as ASOs, siRNA, miRNA, mRNA, aptamers, shRNA, and CRISPR/Cas systems are enabling ...
Wangzheqi Zhang, Aimin Jiang, Bin‐Kui Jia, Yuming Jin, Yinghu Chen, Zhaoyu Li, Yan Liao, Haoling Zhang, Zhiheng Lin, Xiao Fang, Linhui Wang   +10 more
wiley   +1 more source

Effects of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and nonalcoholic fatty liver disease: A cohort study. [PDF]

Saudi Pharm J
Naguib R, Aleyeidi N, Naguib H.
europepmc   +1 more source

The Impact of Previous HBV Infection on The Severity of Nonalcoholic Fatty Liver Disease

Fathy Ghamry Abdel-Razek, Amin Mohamed Abdel Baki, Sara Abdel‐Latif, Ahmed Eliwa, Mohammed Salah Eldin Mohammed Elgendar   +4 more
openalex   +1 more source

HSD17B7 Counters Bone Loss in Estrogen Deficiency via Estrogen Receptor Stabilization and Mediates the Effect of Raloxifene

MedComm, Volume 7, Issue 2, February 2026.
In this study, we identified a previously unrecognized function of HSD17B7 as an ERα‐binding protein that serves as a coactivator to influence trabecular bone mass in estrogen deficiency. Specifically, deleting HSD17B7 in myeloid cells enhanced the number of osteoclasts and decreased trabecular bone mass post‐OVX, compared with control OVX, mirroring ...
Junyue Zhang, Yiping Song, Jeong‐Hyun Koo, Si Chen, Kyu Yun Jang, Sun‐Jung Yoon, Jung Ryul Kim, Young Jae Moon   +7 more
wiley   +1 more source